Trial Profile
Bipolar Androgen Therapy Plus Olaparib in Patients With Castration-Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Testosterone cipionate (Primary) ; Testosterone enanthate (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Mar 2024 Planned End Date changed from 8 Mar 2025 to 12 Apr 2024.
- 01 Apr 2023 Planned End Date changed from 8 Mar 2023 to 8 Mar 2025.
- 09 Mar 2021 Status changed from recruiting to active, no longer recruiting.